Skip to results
Modify your search
NARROW
1-20 of 31
Authors: Jörg Felsberg
Journal Article
EPEN-14. MOLECULAR MARKERS AND PREDICTORS OF OUTCOME FOR PAEDIATRIC INTRACRANIAL EPENDYMOMA IN THE PROSPECTIVE, MULTICENTRE E-HIT2000 TRIAL AND SUBSEQUENT HIT-REGISTRIES: A POOLED ANALYSIS OF 244 PATIENTS
Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.216
Published: 18 June 2024
Journal Article
PATH-19. PROGNOSTIC FACTORS, RESPONSE TO TREATMENT, AND OUTCOME OF PATIENTS WITH ISOCITRATE DEHYDROGENASE (IDH)-MUTANT ASTROCYTOMA, CNS WHO GRADE 4
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v171, https://doi.org/10.1093/neuonc/noad179.0649
Published: 10 November 2023
Journal Article
CTNI-34. ZOTIRACICLIB (TG02) FOR NEWLY DIAGNOSED GLIOBLASTOMA IN THE ELDERLY OR FOR RECURRENT GLIOBLASTOMA: FINAL RESULTS OF THE EORTC 1608 STEAM TRIAL
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v81–v82, https://doi.org/10.1093/neuonc/noad179.0316
Published: 10 November 2023
Journal Article
Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis
Neuro-Oncology, Volume 24, Issue 9, September 2022, Pages 1509–1523, https://doi.org/10.1093/neuonc/noac068
Published: 21 March 2022
Journal Article
The molecular evolution of glioblastoma treated by gross total resection alone
Neuro-Oncology, Volume 23, Issue 2, February 2021, Pages 334–336, https://doi.org/10.1093/neuonc/noaa261
Published: 11 November 2020
Journal Article
BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii14, https://doi.org/10.1093/neuonc/noaa215.056
Published: 09 November 2020
Journal Article
EDITOR'S CHOICE
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma
Neuro-Oncology, Volume 22, Issue 8, August 2020, Pages 1162–1172, https://doi.org/10.1093/neuonc/noaa033
Published: 17 February 2020
Journal Article
ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi25–vi26, https://doi.org/10.1093/neuonc/noz175.095
Published: 11 November 2019
Journal Article
MEDU-20. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA
Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii107, https://doi.org/10.1093/neuonc/noz036.179
Published: 23 April 2019
Journal Article
LGG-08. PROTEOGENOMICS REVEALS TWO DISTINCT BIOLOGICAL PILOCYTIC ASTROCYTOMA SUBGROUPS
Neuro-Oncology, Volume 21, Issue Supplement_2, April 2019, Page ii100, https://doi.org/10.1093/neuonc/noz036.151
Published: 23 April 2019
Journal Article
ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi25, https://doi.org/10.1093/neuonc/noy148.091
Published: 05 November 2018
Journal Article
RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi240, https://doi.org/10.1093/neuonc/noy148.993
Published: 05 November 2018
Journal Article
CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi48–vi49, https://doi.org/10.1093/neuonc/noy148.193
Published: 05 November 2018
Journal Article
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment
Neuro-Oncology, Volume 20, Issue 12, December 2018, Pages 1616–1624, https://doi.org/10.1093/neuonc/noy118
Published: 24 July 2018
Journal Article
LGG-38. PROTEOGENOMICS REVEALS THREE DISTINCT BIOLOGICAL PILOCYTIC ASTROCYTOMA SUBGROUPS
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Page i112, https://doi.org/10.1093/neuonc/noy059.379
Published: 22 June 2018
Journal Article
MBRS-16. HDAC AND NFκB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA
Neuro-Oncology, Volume 20, Issue suppl_2, June 2018, Page i131, https://doi.org/10.1093/neuonc/noy059.461
Published: 22 June 2018
Journal Article
ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi2, https://doi.org/10.1093/neuonc/nox168.004
Published: 06 November 2017
Journal Article
ACTR-23. MOLECULAR GENETIC, HOST-DERIVED AND CLINICAL DETERMINANTS OF LONG-TERM SURVIVAL IN GLIOBLASTOMA: FIRST RESULTS FROM THE BRAIN TUMOR FUNDERS’ COLLABORATIVE CONSORTIUM
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi5–vi6, https://doi.org/10.1093/neuonc/nox168.018
Published: 06 November 2017
Journal Article
CSIG-04. WNT SIGNALING REGULATES ALDEHYDE DEHYDROGENASE 3A1 (ALDH3A1) TO INDUCE TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA CELLS
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Page vi50, https://doi.org/10.1093/neuonc/nox168.199
Published: 06 November 2017
Journal Article
TRTH-28. HIGH THROUGHPUT SCREENING OF NOVEL HISTONE DEACETYLASE INHIBITORS FOR EPIGENETIC THERAPY OF PRIMARY BRAIN TUMORS
Neuro-Oncology, Volume 19, Issue suppl_4, June 2017, Pages iv57–iv58, https://doi.org/10.1093/neuonc/nox083.238
Published: 31 May 2017
